You are here:

Biphasic insulin aspart 30 (NovoMix 30®)


Recommended for general use within NHS Scotland.


In trials of 12 weeks duration, biphasic insulin aspart has demonstrated similar effects on HbA1c levels to biphasic human insulin 30 and biphasic insulin lispro Mix 25. Biphasic insulin aspart 30 has demonstrated similar effects to its competitor insulins and therefore is an effective treatment for diabetes at broadly similar costs.

Drug Details

Drug Name: Biphasic insulin aspart 30 (NovoMix 30®)
SMC Drug ID: 06/02
Manufacturer: Novo Nordisk Ltd
Indication: Diabetes mellitus
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 6 June 2003

Archived Advice

Full submission 5 July 2002